ArticleAnalytical chemistry2026
Dual Paper-Based Electrochemical Device for Multiplex Detection of Triple-Negative Breast Cancer miRNA Signatures.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this technical note, we demonstrate how the merging of paper-based screen-printing, engineered probes, and multiplexing might offer a potent tool toward the analysis of cancer-related miRNA signatures. In fact, while single miRNA detection cannot be associated with a health condition, the detection of miRNA signatures (more than one sequence) offers a more comprehensive reflection of disease biology. The two working electrodes are engineered with rationally designed capture probes modified with two different redox mediators, namely methylene blue and ferrocene; this is necessary to discriminate against different miRNAs, i.e., miRNA-21 and miRNA-101, which are dysregulated in triple-negative breast cancer. The use of ferrocene and methylene blue as redox mediators enables independent, interference-free target detection within a single electrochemical system. The analytical characterization of the dual sensor for both analytes is consistent with the single systems, enabling their simultaneous detection in a wide concentration range (0.1-1000 nM). The platform achieves clinically relevant low-nanomolar limits of detection in both PBS and untreated human serum, while demonstrating excellent repeatability with a relative standard deviation of ∼4%, a rapid assay time of 30 min and straightforward operational procedures. Importantly, the proof-of-concept analysis performed in untreated spiked serum samples demonstrated reliable detection within a complex biological matrix. These findings highlight the potential of multiplex miRNA signature analysis in biofluids and warrant further evaluation in clinically relevant samples. Overall, this fast, low-cost paper-based platform enables multiplex analysis at the point of care and can be readily expanded to larger miRNA panels, providing a promising foundation for future diagnostic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.